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Many conventional chemotherapeutic drugs exert their cytotoxic function by inducing DNA
damage in the tumor cell. Therefore, a cell-inherent DNA repair pathway, which reverses
the DNA-damaging effect of the cytotoxic drugs, can mediate therapeutic resistance to
chemotherapy. The monofunctional DNA-alkylating agent temozolomide (TMZ) is a com-
monly used chemotherapeutic drug and the gold standard treatment for glioblastoma
(GBM). Although the activity of DNA repair protein O6-methylguanine-DNA methyltrans-
ferase (MGMT) has been described as the main modulator to determine the sensitivity of
GBM toTMZ, a subset of GBM does not respond despite MGMT inactivation, suggesting
that another DNA repair mechanismmay alsomodulate the tolerance toTMZ. Considerable
interest has focused onMGMT, mismatch repair (MMR), and the base excision repair (BER)
pathway in the mechanism of mediating TMZ resistance, but emerging roles for the DNA
strand-break repair pathway have been demonstrated. In the ﬁrst part of this review article,
we brieﬂy review the signiﬁcant role ofMGMT,MMR, and the BER pathway in the tolerance
toTMZ; in the last part, we review the recent publications that demonstrate possible roles
of DNA strand-break repair pathways, such as single-strand break repair and double-strand
break repair, as well as the Fanconi anemia pathway in the repair process after alkylating
agent-based therapy. It is possible that all of these repair pathways have a potential to
modulate the sensitivity to TMZ and aid in overcoming the therapeutic resistance in the
clinic.
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INTRODUCTION
Glioblastoma (GBM) is the most common malignant tumor of
the brain in adults (Wen and Kesari, 2008). Due to the invasive
nature of the tumor, complete surgical extirpation of the tumor
cell is rarely achieved. The current gold standard for treatment
of patients with GBM is multidisciplinary management by max-
imum tumor resection with concomitant temozolomide (TMZ)
chemotherapy and radiotherapy (Reardon et al., 2006; Stupp et al.,
2006). Although TMZ chemotherapy signiﬁcantly prolongs the
survival of patient with newly diagnosed GBM, the median sur-
vival is still between 12 and 15 months (Reardon et al., 2006;
Stupp et al., 2009), indicating that overcoming TMZ resistance
is a critical issue to improve treatment outcomes. Chemoresis-
tance in the tumor can be caused by several cellular factors such
as increased efﬂux ability of chemotherapeutic drugs, expres-
sion of anti-apoptotic proteins, and activation of DNA repair
pathways.
Although all of the conventional chemotherapeutic drugs,
including TMZ, exert their cytotoxic function by damaging DNA
and inducing cell death in tumors, normal cells possess several
DNA repair systems to combat DNA damage (Friedman et al.,
2000; Fu et al., 2012). In cancer cells, DNA repair systems are
frequently altered compared to normal cells. Some DNA repair
pathways are impaired due to genomic mutations and epigenetic
events and therefore depend on other repair pathways to recover
from the DNA damage. The DNA repair activity can have a nega-
tive effect on the sensitivity to cytotoxic chemotherapeutic drugs
(Madhusudan and Hickson, 2005; Ding et al., 2006; Helleday
et al., 2008). Cytotoxicity of TMZ is provoked by TMZ-generated
O6-methylguanine-DNA adducts, which is repaired by the O6-
methylguanine-DNA methyltransferase (MGMT) repair enzyme,
thereby suppressing cytotoxicity. Thus, these data suggest that acti-
vation of the MGMT enzyme is associated with resistance to TMZ
therapy (Friedman et al., 2000; Sarkaria et al., 2008; Fu et al., 2012).
Indeed, it has been reported that GBM patients with MGMT pro-
moter methylation respond better than unmethylated patients for
the concomitant TMZand radiotherapy,makingMGMTmethyla-
tion a critical biomarker for predicting sensitivity to TMZ therapy.
However, emerging evidence indicates that MGMT-independent
DNA repair pathways play a role in mediating the therapeutic
response to TMZ in GBM (Kondo et al., 2010b; Alexander et al.,
2012; Bartek et al., 2012).
DNA REPAIR PATHWAYS AS A TARGET OF CANCER THERAPY
Cellular DNA is exposed to various kinds of DNA damage induc-
ers. Reactive oxygen species (ROS), ultraviolet (UV) light, and
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many kinds of chemicals, for example, carcinogens from cigarette
smoking, are well known inducers of DNA damage in vivo. To
combat this DNA damage, normal cells have intrinsic DNA dam-
age response (DDR) systems to protect them from endogenous
and exogenous DNA damage inducers (Harper and Elledge, 2007;
Jackson and Bartek, 2009; Ciccia and Elledge, 2010; Lord and Ash-
worth, 2012). DDR systems provoke different biological processes
depending on the type and strength of the damage, such as DNA
repair, cell cycle arrest, cell death, and cell senescence. The cell cycle
is arrested during the DNA repair process as long as normal DNA
repair capacity is preserved. However, when the normal repair
process is impaired or altered, DNA damage is not repaired, trig-
gering cell death in the tumor cells. Cytotoxic anti-cancer drugs
are used in the clinic to induce DNA damage in cells for the pur-
pose of triggering cell death directly and indirectly following DNA
replication. Therefore, the DNA repair status in the tumor cells is
associated with the therapeutic response to the anti-cancer drug,
establishing DNA repair pathways as promising targets for can-
cer treatment, including GBM (Madhusudan and Hickson, 2005;
Ding et al., 2006; Helleday et al., 2008; Al-Ejeh et al., 2010; Kondo
et al., 2010b; Alexander et al., 2012; Aziz et al., 2012; Bouwman and
Jonkers, 2012).
DNA damage is repaired through a variety of DNA repair path-
ways, depending on the type of DNA damage. DNA repair path-
ways consist of the direct repair (DR), base excision repair (BER),
nucleotide repair (NER), mismatch repair (MMR), and DNA
strand-break repair pathways, among others (Harper and Elledge,
2007; Jackson and Bartek, 2009; Ciccia and Elledge, 2010). The
Fanconi anemia (FA) pathway repairs interstrand cross-links
(ICLs). DNA repair pathway functions are redundant in the con-
text of cellular DNA damage, and have back-up systems, making
the response toDNAdamagemore complex. In addition, it should
be stressed that even though chemotherapeutic drugs, including
TMZ, do not directly induce DNA double-strand breaks (DSBs),
unrepaired damaged bases and nucleotides ultimately cause DSBs.
Thus, theDNA strand-break repair pathway should also be consid-
ered for investigation into themechanismsunderlying resistance to
chemotherapy. Another key concept for targeting the DNA repair
strategy is the synthetic lethal approach (Moeller et al., 2009; Rein-
hardt et al., 2009; Chan and Giaccia, 2011). As mentioned earlier,
it is possible that if one of the critical DNA repair pathways is
impaired, another pathway in the tumor cell will be activated. In
these situations, only attenuating the affected DNA repair path-
way effectively confers a strong cytotoxic effect that prevents tumor
cells from replicating, but does not affect normal cells. This treat-
ment strategy, called “synthetic lethality,” is effective as a targeted
therapy for a DNA repair pathway (Reinhardt et al., 2009). Indeed,
there have been numerous reports demonstrating the clinical util-
ity of the concept of the synthetic lethality approach in various
solid tumors (Chan and Giaccia, 2011).
DEFINITE ROLES OF MGMT, MMR, AND BER PATHWAYS IN
THE TOLERANCE OF TMZ TREATMENT
Temozolomide is a monofunctional SN-1 alkylating agent that
can modify nitrogen atoms in the DNA ring and the extracyclic
oxygen group. TMZ is chemically converted to MTIC (5-3-
(methyltriazen-1-yl) imidazole-4-carboximide) at physiologic pH
and degrades to methyldiazonium cation, which transfers methyl
groups to DNA (Friedman et al., 2000). The common site of
methylation is at the N7 position of guanine (N7-MeG; 60–80%)
followed by the N3 position of adenine (N3-MeA; 10–20%) and
the O6 position of guanine (O6-MeG; 5–10%; Friedman et al.,
2000; Fu et al., 2012; Figure 1).
O6-METHYLGUANINE-DNA METHYLTRANSFERASE
Although O6-MeG is the least frequently alkylated DNA adduct,
O6-MeG is a major cytotoxic adduct induced by TMZ treatment
(Figure 1). Therefore, the DR pathway by MGMT, which removes
TMZ-generated O6-MeG by transferring the methyl adducts to its
own cysteine residues, can mediate tolerance to TMZ treatment.
This theoretical function has been validated by many investigators
using a preclinical model (Pegg, 1990; Gerson, 2004), and MGMT
methylation has been linked to therapeutic sensitivity to TMZ in
the clinical study (Hegi et al., 2005; Stupp et al., 2009). Given that
MGMT inactivation is a molecular biomarker of good response
to TMZ, several strategies have been investigated to reduce the
MGMT activity for the purpose of enhancing TMZ sensitivity
(Hegi et al., 2008). O6-benzylguanine (O6-BG) has been known
to inhibit MGMT activity and enhance the cytotoxicity of TMZ
in vitro (Wedge and Newlands, 1996). However, the result of
recent clinical trial demonstrated that the combination of O6-
BG with TMZ did not show clinical beneﬁt for recurrent and
TMZ-resistant malignant glioma patients (Quinn et al., 2009).
In addition, because alternative TMZ dosing regimens reduce
MGMT activity, several dose-dense (dd) TMZ regimens have been
investigated in the clinic (Wick et al., 2009; Neyns et al., 2010).
Although the clinical signiﬁcance of these dd TMZ regimens has
not been determined, the recent study did not demonstrate the
improved efﬁcacy of dd TMZ regimens (Gilbert et al., 2011). Fur-
ther studies are underway to evaluate the signiﬁcance of dd TMZ
regimens.
MISMATCH REPAIR
Mismatched repair mends DNA damage and base mismatches
as well as incorrect insertions/deletions arising from DNA repli-
cation. In MMR, base mismatches are recognized by the het-
erodimers of MSH2 and MSH6, which recruit another het-
erodimeric complex of MLH1 and PMS2, thereby regulating
the repair process (Stojic et al., 2004a; Figure 2). TMZ-induced
O6-MeG is not repaired by MGMT. Unrepaired O6-MeG can
pair with cytosine (C) or thymidine (T). The O6-MeG/C or
O6-MeG/T is recognized by the MMR system and only newly
synthesized strands are excised, keeping O6-MeG intact. When
another strand is generated, this repair cycle is repeated. This
“futile cycle” provokes replication fork arrest during DNA syn-
thesis, and cytotoxicity is induced by causing DSB formation
(Wang and Edelmann, 2006; Fu et al., 2012; Figure 1). Thus, the
normal function of the MMR pathway is a prerequisite for O6-
MeG-induced cytotoxicity. The inactivation of MMR has been
associated with tolerance to the cytotoxic effects of alkylating
agents (Friedman et al., 1997; D’Atri et al., 1998; Fink et al., 1998;
Kinsella, 2009).
Although only a few gene mutations of MMR genes such as
MSH2, MSH6, MLH1, and PMS2 in GBM have been discovered,
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FIGURE 1 |Temozolomide function and activated DNA repair pathway.
Temozolomide (TMZ) is chemically converted to MTIC (5-3-(methyltriazen-1-yl)
imidazole-4-carboximide) at physiologic pH and degrades to a
methyldiazonium cation, which transfers a methyl group to DNA. The most
common site of methylation is N7-MeG (60–80%) followed by N3-MeA
(10–20%) and O6-MeG (5–10%).When active MGMT is present, O6-MeG is
repaired without cytotoxicity. When MGMT is inactivated or does not have
the potential to completely repair O6-MeG, unrepaired O6-MeG is
continuously repaired by the futile cycle of MMR, which ultimately
induces cell death by provoking double-strand breaks (DSB).When MMR
does not function properly, genomic instability is ampliﬁed. N7-MeG and
N3-MeA is repaired by BER. If not repaired, alkylated bases cause a
replication stall and collapse of the replication fork, generating single-strand
breaks (SSBs), which ultimately induce DSB. It is possible that SSB
and DSB repair pathways are activated and diminish the cytotoxic effects
of TMZ.
recent investigations have revealed that MSH6 mutations arise in
GBMs during TMZ therapy and mediate TMZ resistance. Hunter
et al. (2006) identiﬁed somaticMSH6mutations in recurrentGBM
tissues after alkylating therapy with no mutations in matched
pretreatment samples, suggesting that MSH6 mutations medi-
ate clinical resistance to TMZ. Cahill et al. (2007) also showed
that although MSH6 mutations were not observed in any pre-
treatment GBM specimens, 3 of 14 (21%) recurrent cases had
somatic mutations, and 7 of 17 (41%) recurrent tumors showed
decreased expression of MSH6, compared with the matched pre-
treatment specimens, after concomitant TMZ and radiotherapy,
indicating that loss of MSH6 function is associated with tumor
recurrence during TMZ treatment. Their subsequent studies con-
ﬁrmed MSH6 mutations in post-treatment TCGA samples, but
the absence of mutations in matched pretreatment samples, and
demonstrated that MSH6 mutations mediate TMZ resistance in
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FIGURE 2 | Schematic illustration of DNA repair pathways and
implicated proteins. Mismatch repair (MMR) functions in the repair of base
substitution mutations as well as small insertions/deletions caused by
replication errors. The heterodimeric complex of MSH2 and MSH6 recognizes
base mismatches and single-base insertions/deletions, whereas the MSH2
and MSH6 complex (not described in this schema) detect larger
insertions/deletions. These complexes recruit another heterodimeric complex
made up of MLH1 and PMS2 to initiate the repair process by excision of
mismatches and insertions/deletions and re-synthesis of the DNA strand. In
base excision repair (BER), a damaged base is recognized by a DNA
glycosylase enzyme. Of all DNA glycosylase, DNA glycosylase (MPG)
[alkylpurine-DNA-N -glycosylase (APNG)] recognizes and removes alkylated
bases before apurinic/apyrimidinic endonuclease 1 (APE1) recognizes the
abasic sites and cleaves the 5′ end of the DNA. In the major BER pathway, as
a short-patch pathway, DNA polymerase β (polyβ) excises the 3′ end of the
DNA and ﬁlls the gap. Finally, the XRCC1-ligase III complex catalyzes the
formation of phosphodiester bonds and completes the repair process. Poly
(ADP-ribose) polymerase (PARP) recognizes single-strand breaks and initiates
the repair process in an overlapping manner with BER. For DSB repair,
non-homologous end-joining (NHEJ) and homologous recombination (HR) are
utilized in the repair mechanism. In NHEJ, DSB are recognized by the Ku70/80
proteins, which bind and activate the protein kinase DNA-PKcs, recruiting
XRCC4 and DNA ligase IV (Lig IV) to seal the gap. In HR, the
MRE-11-RAD50-NBS1 (MRN) complex act as a sensor of DSB and binds
to the break ends. Ataxia telangiectasia mutated (ATM) is then recruited to
the sites of the breaks where ATM is phosphorylated and activates H2AX,
generating phosphorylated H2AX (γ H2AX). DNA damage checkpoint protein
1 (MDC1) binds γ H2AX and the recombination process begins. Replication
stress causes single-stranded DNA and induces subsequent DSB. In this
case, single-stranded DNA is bound by replication protein A (RPA), which
recruits ATR and ATR-interacting protein (ATRIP) to the break site. Rad17 and
9-1-1 are subsequently recruited to ATR-ATRIP, which is ﬁnally activated with
the aid of DNA topoisomerase II-binding protein 1 (TOPBP1). In the process
of HR, the BRCA1 complex with MDC1 has an essential role in damage
detection. The subsequent BRCA1-BRCA1-partner and localizer of BRCA2
(PALB2)-BRCA2 complex is important in mediating HR. BRCA2-mediated
Rad51 recruitment is crucial for HR. Rad52 is also needed for RAd51 to
enable access to single-stranded DNA coated with RPA. The Fanconi anemia
(FA) pathway functions during translesion DNA synthesis (TLS) in the repair of
DNA interstrand cross-links (ICLs). ICLs are recognized by FANCM and the FA
core complex, which monoubiquitinates FANCD2 and FANCI, thereby
recruiting nucleases and other mediator proteins to facilitate the repair
process. Recent studies have shown that the FA pathway regulates not
only ICL, but also HR, possibly mediating BRCA2 and Rad51 function. The
MGMT and nucleotide excision repair (NER) pathways are not described in
this schema.
an in vitro tumor model (Yip et al., 2009). Moreover, the Ger-
man Glioma Group recently reported that reduced expression of
MMR protein was associated with recurrence of GBM after TMZ
treatment (Felsberg et al., 2011). These results support the notion
that a normal MMR system is indispensable for TMZ-induced
cytotoxicity.
BASE EXCISION REPAIR
Base excision repairmends DNA from the damaging effects of oxi-
dation, alkylation, deamination, and single-strand breaks (SSBs).
TMZ-induced N7-MeG and N3-MeA is sensed by the BER path-
way and the repair process is initiated (Fu et al., 2012; Figure 1).
BER has been reported to play a role in the tolerance of TMZ
resistance (Trivedi et al., 2005). DNA glycosylases play a role
in recognizing and excising damaged bases, and initiating the
repair process. Among the 11 mammalian DNA glycosylases,
N-methylpurine DNA glycosylase (MPG) [or alkylpurine-DNA-
N-glycosylase (APNG)] is a DNA glycosylase that excises alkylated
bases from DNA (Jacobs and Schar, 2012). After damaged bases
are removed by DNA glycosylase, apurinic/apyrimidinic endonu-
clease 1 (APE1) recognizes the abasic sites and cleaves the 5′ end
of the DNA. Then, DNA polymerase β (poly β) along with the
XRCC1-Ligase III (Lig III) complex complete the repair process
(Fortini and Dogliotti, 2007; Svilar et al., 2011; Figure 2).
The expression of DNA glycosylases has been associated with
the sensitivity to alkylating agents. Agnihotri et al. (2012) recently
demonstrated that APNG expression modulates the repair of
TMZ-inducedDNAdamage andAPNG confers resistance to TMZ
in in vitro and in vivo models of GBM. They also demonstrated
thatAPNG is epigenetically silenced in theGBM tissues andAPNG
confers poor overall survival in GBM patients, indicating that
APNG can be a molecular target for overcoming TMZ resistance.
It has also been shown that inhibition of polyβ increases the sen-
sitivity to TMZ-induced toxicity, indicating that the BER pathway
may be a therapeutic target for enhanced TMZ sensitivity (Trivedi
et al., 2005).
Frontiers in Oncology | Radiation Oncology December 2012 | Volume 2 | Article 186 | 4
“fonc-02-00186” — 2012/12/3 — 20:52 — page 5 — #5
Yoshimoto et al. DNA repair pathways in gliomas
POSSIBLE ROLES OF OTHER REPAIR PATHWAYS IN
MEDIATING TMZ RESISTANCE
SINGLE-STRAND BREAK REPAIR PATHWAY
Poly(ADP-ribose) polymerase (PARP) recognizes SSBs and initi-
ates the repair process. PARP uses NAD+ as a substrate to catalyze
the covalent attachment of PARpolymers on itself andother accep-
tor proteins, recruiting DNA repair proteins to the damaged site,
which facilitates downstream repair processes (Kim et al., 2005;
Schreiber et al., 2006; De Vos et al., 2012; Luo and Kraus, 2012).
After SSBs are recognized by PARP, the repair process can be ini-
tiated by a shared process with the BER pathway (Almeida and
Sobol, 2007; Figure 2). Thus, PARP is a crucial regulator of not
only SSB repair, but also of the BER pathway, which makes PARP
a therapeutic target in modulating the DNA repair system. Tar-
geted drugs that inhibit PARP activity have been developed, and it
has been shown that these PARP inhibitors signiﬁcantly enhance
the cytotoxicity of conventional anticancer drugs including those
used to treat GBM (Malanga and Althaus, 2005; Chalmers, 2010;
Heitz et al., 2010; Leonetti et al., 2012). Due to these therapeu-
tic effects in preclinical studies, several trials are underway using
PARP inhibitors for GBM patients (Leonetti et al., 2012).
The rationale for this treatment is to potentiate the therapeutic
effects of DNA-damaging agents using PARP inhibitors. It has
been shown that a combination of TMZ and PARP inhibitors
enhance the cytotoxic effects of TMZ in GBM preclinical mod-
els (Tentori et al., 2002, 2003; Miknyoczki et al., 2003; Calabrese,
2004). In addition, it has been shown that PARP inhibition can
overcome the resistance to TMZ in MMR-deﬁcient cells (Curtin
et al., 2004; Cheng et al., 2005). Based on these promising results,
several clinical trials of PARP inhibitors for GBM are ongo-
ing to increase the therapeutic effect of TMZ (Chalmers, 2010;
Leonetti et al., 2012).
Another promising strategy for PARP inhibitor therapy is
monotherapy under the concept of synthetic lethality (Mangerich
and Burkle, 2011). A growing body of evidence suggests that PARP
inhibition has a signiﬁcant cytotoxic effect for the BRCA1- and
BRCA2-mutated breast and ovarian cancers (Farmer et al., 2005;
Fong et al., 2009; Venkitaraman, 2009; Rehman et al., 2010). In
BRCA-mutated tumors, the DSB repair pathway by homologous
recombination (HR) processes (described in the next section) is
impaired. Therefore, the DNA repair process is dependent on
the PARP repair pathway, where PARP inhibition has detrimental
effects on the tumor cells. Although this synthetic lethal approach
seems to be a promising therapy, BRCAmutation is rarely reported
in GBM (Parsons et al., 2008; TCGA, 2008). However, it has
recently been reported that mutation of tumor suppressor PTEN
is linked to impairment of a HR repair pathway, implicating syn-
thetic lethal targeting of PTEN mutant cells with PARP inhibitors
(Shen et al., 2007; Mendes-Pereira et al., 2009; McEllin et al., 2010;
Ming and He, 2012). Given that PTEN mutation is identiﬁed in
about one-third of GBM patients (Parsons et al., 2008; TCGA,
2008), PARP inhibitor monotherapy has the potential to be an
effective treatment strategy for the PTEN-mutatedGBM.Recently,
several preclinical studies demonstrated that up-regulation of a
HR pathway correlates with the sensitivity to combination ther-
apy of TMZ and PARP inhibitors (Liu et al., 2009; Loser et al.,
2010). Further investigation is needed to evaluate the status of HR
in PTEN-mutated GBM and the response to TMZ in combination
with a PARP inhibitor.
DOUBLE-STRAND BREAK PATHWAY
Double-strand break is repaired by two major mechanisms: non-
homologous end-joining (NHEJ) and HR (Figure 2). NHEJ
repairs DNA blunt-ends breaks throughout the cell cycle and
repairs DSB even when there are no templates for recombination
regardless of the cell cycle. In contrast, the HR pathway repairs
the DSB by homology-mediated recombination processes using
sister-chromatid sequences as the template. Thus, HR functions
only in the S and G2 phases of the cell cycle, indicating that HR
can function only in proliferating tumor cells. With the exception
of a topoisomerase II inhibitor and radiotherapy,most of the anti-
cancer drugs, such as alkylating agents and replication inhibitors,
do not induce DSB directly. However, when bases damaged by
cytotoxic drugs are not repaired by BER or the single-strand repair
pathway, DNA replication errors cause replication stress (repli-
cation stalls or a replication fork collapses), resulting in DSB.
Accumulating evidence indicates that the HR process may play
an important role in mediating DSB repair after replication stress
(Helleday et al., 2007; Helleday, 2010; Roy et al., 2012). Theoreti-
cally, TMZ ultimately induces tumor cell death by provoking DSB.
Taken together, it is possible that the status of DSB repair activity in
the tumor cell has the potential to determine the clinical response
to TMZ treatment. Indeed, there have been several reports of the
signiﬁcant role of DSB repair proteins in determining the sensi-
tivity to TMZ in preclinical GBM models; these will be described
below.
Within a fewminutes of damage,NHEJ repair bluntDSB,which
are recognized by the Ku70/80 proteins and bind with the protein
kinase DNA-PKcs, recruiting XRCC4 and DNA ligase IV (Lig IV)
to seal the gap (Figure 2). Given that NHEJ functions to blunt
the DSB, independent of the tumor cell cycle, a signiﬁcant role
in the repair process of radiotherapy in GBM has been reported
(Mukherjee et al., 2009; Zhuang et al., 2011). Although a possible
role for the NHEJ pathway in the sensitivity of TMZ in GBM cells
has been reported, only a few reports have documented this result
(Fischer and Meese, 2007; Roos et al., 2007; Kondo et al., 2010a).
Homologous recombination is initiated by 5′–3′ resection at
two-ended DSB, generating single-stranded DNA. The MRE-11-
RAD50-NBS1 (MRN) complex acts as a sensor of DSB and binds
to a break at the ends. Ataxia telangiectasia mutated (ATM) is then
recruited to the sites of the breaks where ATM is phosphorylated
and activates H2AX, generating phosphorylated H2AX (γH2AX).
DNA damage checkpoint protein 1 (MDC1) binds γH2AX and is
processed by a recombination process (Figure 2). In contrast to the
two-ended DSB described above, DNA replication stress is known
to cause one-ended DSB, generating single-stranded DNA (Helle-
day et al., 2007). In these situations, ATM and Rad3-related (ATR)
signaling is activated to repair one-ended DSB by HR (Cimprich
and Cortez, 2008; Flynn and Zou, 2011). Single-stranded DNA
is bound by replication protein A (RPA), which recruits ATR and
ATR-interacting protein (ATRIP) to the break site. In the pres-
ence of this complex, Rad17 and 9-1-1 are subsequently recruited.
The ATR-ATRIP pathway is ﬁnally activated with the aid of DNA
topoisomerase II binding protein 1 (TOPBP1). HR is mediated
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by proteins of BRCA1, PALB2, and BRCA2 in association with
effector proteins Rad51 and Rad52 (Figure 2).
As described earlier, TMZ induced O6-MeG mismatch lead to
the DSB by the futile cycle (Roos and Kaina, 2012). In addition,
althoughTMZdoes not involveDSB formationdirectly, it has been
reported that TMZ can provoke HR with a potency more than 10-
fold that of ionizing radiation, which is a known DSB inducer
(Helleday, 2010). These results indicate that signaling molecules
implicated in the DSB pathway play a role in mediating TMZ sen-
sitivity. Indeed, NBS1 (a member of the MRN complex), Rad51,
and BRCA2, all signaling proteins implicated in the DSB pathway,
have been reported to be modulators of TMZ sensitivity in an
in vitro tumor model (Eich et al., 2010; Quiros et al., 2011; Short
et al., 2011). Moreover, several studies have shown that ATM,ATR,
andMRNproteins can contribute the TMZ-inducedG2 arrest and
cytotoxicity in a MMR-dependent manner, suggesting that these
molecules may be potential targets to overcome TMZ resistance
(Caporali et al., 2004; Stojic et al., 2004b; Mirzoeva et al., 2006;
Schroering et al., 2009).
FANCONI ANEMIA PATHWAY
Fanconi anemia is genomic instability syndrome characterized by
developmental abnormalities in major organ systems, bone mar-
row failure, and a high predisposition to cancer (D’Andrea and
Grompe, 2003). FA is currently known to be caused by the muta-
tion of at least one of the 15 FA family genes (Kim and D’Andrea,
2012). The FA pathway is believed to be implicated in the repair
of DNA interstrand cross-linking by cisplatin and topoisomerase
inhibitors, and to mediate resistance to this type of drug. How-
ever, recent evidence demonstrated that the FA pathway may be
implicated in the repair process of alkylation damage by alkylating
agents and in the determination of the therapeutic sensitivity to
alkylating agents (Chen et al., 2007; Kondo et al., 2011).
In the FA pathway, FANCM recognize DNA ICL and initi-
ate the repair pathway by recruiting eight FA core complexes
(FANCA/B/C/E/F/G/L/M) to the damaged site. This FA core pro-
tein complex monoubiquitinates FANCD2 and FANCI, which
interact with DNA repair proteins such as BRCA1, BRCA2
(FANCD1), PALB2 (FANCN), and FANCJ (BACH1/BRIP1), facil-
itating the repair process (Kee and D’Andrea, 2010; Figure 2).
Of all these steps, monoubiquitination of FANCD2 and BRCA2
(FANCD1) is the critical step in the FA repair pathway. A recent
study by Chen et al. (2007) demonstrated that inhibition of
FANCD2 monoubiquitination sensitizes the glioma cell line to
the cytotoxic effects of TMZ, and suggested that the FA path-
way may play some role in TMZ resistance. Furthermore, other
recent studies showed that BRCA2 (FANCD1) plays a predom-
inant role in the repair of DNA damage induced by TMZ, and
inhibiting BRCA2 sensitize the glioma cell lines to TMZ treatment,
suggesting that BRCA2 is also a molecular target for overcoming
TMZ resistance (Kondo et al., 2011; Quiros et al., 2011). Given
that BRCA2 (FANCD1) functions in mediating HR, this result, as
well as recent studies demonstrating that the FApathway also func-
tions in the repair of DSB, suggests thatmore detailed investigation
into the FA pathway may reveal novel mechanistic ﬁndings related
to the regulation of the cellular processing after TMZ-induced
cytotoxicity.
CONCLUDING REMARKS
Although the investigation of DNA repair pathways in the tol-
erance of TMZ chemotherapy has been focused on the MGMT
and MMR pathways, recent research has demonstrated that the
BER pathway also plays a signiﬁcant role in determining the sen-
sitivity to TMZ. The possible roles of the SSB and DSB repair
pathways in mediating therapeutic resistance to TMZ have also
begun to emerge. Given that each DNA repair pathway does not
function independently of the others, but shows redundancy and
crosstalk, it is possible that a more signiﬁcant role for DNA strand
repair pathways, such as PARP and HR,will be revealed in relation
to TMZ treatment. The response to DNA damage is dependent
on the extent of the DNA damage inﬂicted. Thus, detailed anal-
ysis of complicated repair pathways can aid in identifying new
mechanisms of chemoresistance. Moreover, establishing useful
molecular markers to assess the status of DNA repair in clinical
tissue is mandatory for future studies to develop an effective treat-
ment strategy targeting repair pathways (Jalal et al., 2011). Finally,
chemoresistance is deﬁned not only by the tumor itself, but also by
the tumor microenvironment. The brain tumor stem cell popula-
tion is another critical biological factor in chemoresistance because
the DNA repair pathway is activated in stem cell populations. Fur-
ther investigation should be performed taking these factors into
consideration.
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